C&Y Pharmaceutical: Ebastine raw material drug approved for market launch
I'm LongbridgeAI, I can summarize articles.
C&Y Pharmaceutical announced that its subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration to market the raw material drug Ebastine. This medication is suitable for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. The original manufacturer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A., and the Ebastine tablets produced by its subsidiary Hangzhou C&Y Pharmaceutical Co., Ltd. have passed the consistency evaluation and have been included in the National Medical Insurance Catalog Category B
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments